Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2008
09/02/2008US7420085 Form II; used for facilitating the delivery of active agents, such as insulin, to a target
09/02/2008US7420084 Polymorphic forms of nateglinide
09/02/2008US7420083 For example, (4-{3-[1-(4-tert-butyl-phenyl)-ethylideneaminooxy]-propoxy}-phenyl)-acetic acid; useful for treatment, including the prevention and inhibition, of a wide variety of diseases and disorders including those involving the production and/or action of serine protease inhibitor PAI-1
09/02/2008US7420079 Intermediates for making 1(alpha-amino-1-(cyclopropyl-fused pyrrolidinylcarbonyl)methyl)-3-hydroxyadamantanes, e.g., methyl 3-hydroxy-<a-oxotricyclo[3.3.1.13,7]decane-1-acetate
09/02/2008US7420069 Crystalline composition containing escitalopram
09/02/2008US7420068 Crystals of purified escitalopram oxalate with a broad particle size distribution suitable for use in direct compressionproduced by treating a solution of citalopram with a hydroxyl group scavenger and reacting with oxalic acid; refluxing, cooling, salt formation, seeding, filtration
09/02/2008US7420066 Benzofuran derivatives useful for treating hyper-proliferative disorders
09/02/2008US7420063 2-trifluoroacetylamino-2-[1-trifluoroacetyladamant-10-yl]-ethanoic acid; N-[1-trifluoroacetylamino-1-(1-(hydroxy or trifluoroacetyl)adamant-10-yl)]-methylcarbonyl-2-azabicyclo[3.1.0]hexane; protecting the alcohol and amine with trifluoroacetyl groups, acyl chlorination, amidation, deprotection
09/02/2008US7420061 Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors
09/02/2008US7420059 HMG-CoA reductase inhibitors and method
09/02/2008US7420056 e.g. cyclopentyl-[2-(5-phenylethynyl-thiophen-2-yl)-imidazo[1,2-a]pyrazin-3-yl]-amine; metabotropic glutamate receptor 5 agonist; as production of pharmaceutical analgesic formulations; chronic and non-chronic pain, neuropathic and cancer pain
09/02/2008US7420055 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide
09/02/2008US7420053 2-imino-1,3-thiazine derivatives
09/02/2008US7420050 TGF-β-specific covalently closed antisense molecule
09/02/2008US7420045 IAPs associated cell cycle proteins, compositions and methods of use
09/02/2008US7420029 A tissue-specific transporter function inhibitor has both a ligand structure recognized by a tissue-specific transporter and a polymeric molecular structure incapable of passing through a membrane tissue
09/02/2008US7420028 Replikins and methods of identifying replikin-containing sequences
09/02/2008US7420003 Compounds and a novel process for their preparation
09/02/2008US7420002 Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
09/02/2008US7420001 N-({4'-[(1-benzofuran-2-ylcarbonyl)amino]-1,1'-biphenyl-4-yl}sulfonyl)glycine; metalloproteinase inhibitors; arthritis, macular degeneration, graft versus host disease, cancer, osteoarthritis
09/02/2008US7420000 e.g. 2-((Diethoxvphosphoryl)methylamino)-2-(furan-2-yl)acetic acid; antiinflammatory, antiproliferative agent, viricide, parasiticide; autoimmune, cardiovascular, bone resorption diseases; one-step three-component reaction among amine derivative, carbonyl derivative and organoboron compound
09/02/2008US7419999 Gamma lactams as prostaglandin agonists and use thereof
09/02/2008US7419998 Therapeutic methods and compositions involving isoflavones
09/02/2008US7419997 e.g. N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-fluorobenzenesulfonamide; viricide; papillomaviruses, polyomaviruses, retroviruses, papovaviruses, adenoviruses
09/02/2008US7419996 include a benzimidazole (mebendazole, fenbendazole, omeprazole), a polyol (polyethylene glycol), and a dipolar aprotic solvent (N,N-dimethylacetamide or dimethylsulfoxide); improved drug solubility, drug release from the formulation, and bioavailability
09/02/2008US7419995 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library
09/02/2008US7419994 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2- thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cyloalkenylmethyl) imidazol-2-ones and related compounds
09/02/2008US7419993 Triazolo-epothilones
09/02/2008US7419992 Use of aryl hydrocarbon receptor ligand as a therapeutic intervention in angiogenesis-implicated disorders
09/02/2008US7419991 Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders
09/02/2008US7419990 e.g. benzyl {1-[2-(1-{[1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-4,5-dimethylphenyl]propyl}carbamate; antidiabetic agent, obesity, sexual disfunctions
09/02/2008US7419988 Azaindole inhibitors of aurora kinases
09/02/2008US7419987 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
09/02/2008US7419986 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
09/02/2008US7419985 reuptake of norephinephrine, dopamine, and serotonin inhibitor; furo-, pyrrolo-, and thienyl-tetrahydroisoquinolines, e.g. 2 methyl 4 phenyl 1,2,3,4,8,9 hexahydro furo[2,3 h]isoquinoline; antidepressant, anxiolytic agent; neurological and psychological disorders
09/02/2008US7419984 for uses such as inhibiting the activity of lysophosphatidic acid acyltransferase beta and/or inhibiting the proliferation of a cell (e.g., tumor cell)
09/02/2008US7419983 Gonadotropin-releasing hormone receptor antagonists and methods related thereto
09/02/2008US7419982 Crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts
09/02/2008US7419981 Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
09/02/2008US7419980 Treating conditions improved by monoamine reuptake; 1-[1-(2-naphthyl)-2-piperazin-1-ylethyl]cyclobutanol; sexual disorders, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, hot flashes
09/02/2008US7419979 Derivatives of 6-{4-[4-(1H-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one
09/02/2008US7419978 Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
09/02/2008US7419977 e.g. 1-(9-Benzylamino-10-cyano-imidazo[1,2- alpha ]quinoline-2-carbonyl)morpholine; cardiovascular diseases; acylation of imidazo[1,2- alpha]quinoline acid derivatives by morpholine derivatives
09/02/2008US7419976 Diazepanes derivatives useful as IFA inhibitors
09/02/2008US7419975 Organic compounds
09/02/2008US7419974 Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same
09/02/2008US7419973 Phosphonocephem compound
09/02/2008US7419972 e.g. 3-Hydroxy-2-phenylethinyl-estra-1,3,5(10)-trien-17-one 19; anticarcinogenic, antitumor agent; hormone-dependent tumor disease of a male/female reproductive gland or endometriosis; estrogen-dependent diseases
09/02/2008US7419971 Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application
09/02/2008US7419970 Cosmetic compositions comprising N-acylamino amides
09/02/2008US7419969 N-((hetero)arylalkyl)pyrimidonecarboxamides in which the ring is fused to a C4-7(hetero)cycloalkyl ring, which in turn has a spiro ring attached: e.g., N-[(4-fluorophenyl)methyl]-7',8'-dihydro-3'-hydroxy-8'-methyl-4'-oxo-spiro[cyclopentane-1,9'(6'H)-[4H]pyrazino[1,2-a]pyrimidine]-2'-carboxamide
09/02/2008US7419968 Screening for anticancer drugs for treating cells that endogenously overexpress intracellular thymidylate synthase by contacting the cell with the candidate and (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl L-alaninylphosphoramidate and assaying for cell death
09/02/2008US7419967 e.g. hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-3-(cyclopentyloxy)[(3-[2-(dimethylamino)ethyl]aminophenyl)sulfonyl]amino-2-hydroxypropyl)carbamate; against human immunodeficiency virus, chronic and acute viral infections
09/02/2008US7419966 Viricides; human t-cell leukemia, lymphoma virus
09/02/2008US7419965 Nucleotide lipid ester derivatives
09/02/2008US7419963 Indole antiviral compositions and methods
09/02/2008US7419962 Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation
09/02/2008US7419961 9a-azalides with anti-inflammatory activity
09/02/2008US7419960 Hemiterpene glycosides with anti-platelet aggregation activities from Ilex pubescens
09/02/2008US7419959 D-pyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
09/02/2008US7419958 Antagonists that bind CD1d and inhibit activation of CD1d-restricted natural killer (NK) T cells, agents that block CD1d-specific receptors and CD1d decoys and a carrier or diluent; contact dermatitis for example
09/02/2008US7419936 Optically active 2,5-bisaryl-Δ1-pyrrolines and their use as pest control agents
09/02/2008US7419824 BASB006 polypeptides from Neisseria meningitidis and immunogenic compositions thereof
09/02/2008US7419807 High molecular weight; isolated nucleic acid; use in detecting antibodies in test sample; diagnostic kit
09/02/2008US7419804 CASH (Caspase Homologue) with death effector domain, modulators of the function of FAS
09/02/2008US7419777 Method and quantification assay for determining c-kit/SCF/pAKT status
09/02/2008US7419687 carriers for group IB compounds such as silver nitrate comprising beads made of inert polymers, ceramics or stainless steels, used for treatment of menorrhagia
09/02/2008US7419686 For preventing oral abuse of an oral opioid formulation; provides a negative, "aversive" experience when a large amount of the opioid, e.g., about 2-3 times the usually prescribed dose, is taken by or administered to a physically dependent subject
09/02/2008US7419683 Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
09/02/2008US7419680 For therapy and prophylaxis of osteoporosis and for bone and fracture repair; slow-releasing, will promote bone formation and inhibit bone resorption
09/02/2008US7419678 Coated medical devices for the prevention and treatment of vascular disease
09/02/2008US7419670 Method of treating arthritis with SERP-1 and an immunosuppressant
09/02/2008US7419657 Reducing antibody-mediated lipid peroxidation activity in vascular systems; idiotypic antibodies; chlamydia pneumoniae vaccines
09/02/2008CA2623733A1 Supplements for pain management
09/02/2008CA2466728C Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
09/02/2008CA2461757C Nicotine formulations comprising chocolate and use thereof
09/02/2008CA2461517C Nicotine formulations comprising cocoa and use thereof
09/02/2008CA2440468C Pregabalin lactose conjugates
09/02/2008CA2426956C Pharmaceutical compositions comprising ascomycin derivatives
09/02/2008CA2411412C Indole derivatives useful for the treatment of cns disorders
09/02/2008CA2395037C The use of scopolamine salts
09/02/2008CA2389333C Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
09/02/2008CA2388140C Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
09/02/2008CA2387999C Method and device for detecting and isolating pharmacological compounds being contained in substance mixtures
09/02/2008CA2386813C Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring
09/02/2008CA2384922C Topical glycopyrrolate product for the reduction of sweating
09/02/2008CA2381091C Fat composition
09/02/2008CA2376819C 2-aminoindane derivatives as dermal anesthetic agents
09/02/2008CA2356158C Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
09/02/2008CA2351068C Drug delivery device, especially for the delivery of progestins and estrogens
09/02/2008CA2350609C N-substituted 2-cyanopyrrolidines
09/02/2008CA2325818C Topical immunostimulation to induce langerhans cell migration
09/02/2008CA2318848C 5'-deoxycytidine derivatives
09/02/2008CA2314238C Synthesis of combretastatin a-4 prodrugs and trans-isomers thereof
09/02/2008CA2313633C Method of increasing the production and improving the quality of semen
09/02/2008CA2311486C Crystalline amrubicin hydrochloride
09/02/2008CA2306881C Methods for treating postmenopausal women using ultra-low doses of estrogen
09/02/2008CA2294351C Compounds useful for inhibition of farnesyl protein transferase
09/02/2008CA2293325C 8-iso-prostaglandins for glaucoma therapy
09/02/2008CA2292910C Hair growth compositions and uses